KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Current Taxes (2018 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Current Taxes for 11 consecutive years, with $2.9 million as the latest value for Q1 2026.

  • For Q1 2026, Current Taxes rose 2180.95% year-over-year to $2.9 million; the TTM value through Mar 2026 reached $2.9 million, up 2180.95%, while the annual FY2025 figure was $2.7 million, 7879.41% up from the prior year.
  • Current Taxes hit $2.9 million in Q1 2026 for Ionis Pharmaceuticals, up from $2.7 million in the prior quarter.
  • Across five years, Current Taxes topped out at $31.1 million in Q3 2023 and bottomed at $14000.0 in Q2 2022.
  • Average Current Taxes over 5 years is $5.3 million, with a median of $901000.0 recorded in 2022.
  • Year-over-year, Current Taxes surged 194087.5% in 2023 and then tumbled 99.87% in 2024.
  • Ionis Pharmaceuticals' Current Taxes stood at $6.2 million in 2022, then tumbled by 65.58% to $2.2 million in 2023, then tumbled by 98.42% to $34000.0 in 2024, then soared by 7879.41% to $2.7 million in 2025, then increased by 5.93% to $2.9 million in 2026.
  • According to Business Quant data, Current Taxes over the past three periods came in at $2.9 million, $2.7 million, and $101000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.